FindTrial
Sign In

Efficacy, tolerability and safety of 0.2% Brimonidine-Tartrate for the treatment of acute non-arteritic anterior ischaemic optic neuropathy

Efficacy, tolerability and safety of 0.2% Brimonidine-Tartrate for the treatment of acute non-arteritic anterior ischaemic optic neuropathy (NAION): a 3-month, double-masked, randomised and placebo-controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN72549635
Enrollment
Unknown
Registered
2003-09-12
Start date
2001-07-01
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eye Diseases: Non-arteritic anterior ischemic optic neuropathy Eye Diseases Other disorders of optic [2nd] nerve and visual pathways

Interventions

Randomised controlled trial

Sponsors

Department of Health (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with acute non-arteritic anterior ischemic optic neuropathy

Exclusion criteria

Exclusion criteria: Does not match inclusion criteria

Design outcomes

Primary

MeasureTime frame
Safety of 0.2% Brimonidine-Tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION)—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026